| Literature DB >> 33458383 |
Vicki Trier Taasti1, Ludvig Paul Muren1, Kenneth Jensen2, Jørgen Breede Baltzer Petersen1, Jesper Thygesen3, Anna Tietze4,5, Cai Grau2, David Christoffer Hansen1.
Abstract
BACKGROUND ANDEntities:
Keywords: Dual-energy CT; Head and neck cancer; Proton therapy; Stopping power ratio; Water-equivalent path length
Year: 2018 PMID: 33458383 PMCID: PMC7807876 DOI: 10.1016/j.phro.2018.04.002
Source DB: PubMed Journal: Phys Imaging Radiat Oncol ISSN: 2405-6316
Fig. 1Difference maps for patient No. 2. (a) WEPL difference map. (b) SPR difference map.
WEPL and SPR differences for each individual patient. The WEPL difference is given as the RMS over all rays in absolute values (mm) (2nd column) and relative to the RMS WEPL in the DECT-based SPR map (3rd column) (%), as well as the 2.5% to 97.5% percentiles of the absolute WEPL difference (4th column). No WEPL differences are reported for Group B due to the motion artifacts. The SPR difference is given for ROIs in the cranium bone, brain and eyes (5th–7th column). The SPR difference is given relative to the DECT-based SPR (%) along with the standard error of the mean (SEM) in parenthesis (%).
| WEPL difference | SPR difference | |||||
|---|---|---|---|---|---|---|
| Patient No. | Abs. diff. (mm) | Rel. diff. (%) | Percentiles [2.5%,97.5%] (mm) | Cranium (%) | Brain (%) | Eyes (%) |
| Patient subgroup A | ||||||
| 1 | 1.3 | 1.0 | [−3.7,0.3] | 0.2 (0.1) | −0.5 (0.02) | −1.5 (0.1) |
| 2 | 1.8 | 1.4 | [−4.9,0.04] | −0.2 (0.1) | −0.8 (0.02) | −1.4 (0.1) |
| 3 | 2.2 | 1.7 | [−5.8,−0.1] | −0.4 (0.1) | −1.5 (0.02) | −1.7 (0.1) |
| 4 | 2.2 | 1.6 | [−5.1,0.03] | −0.2 (0.05) | −1.2 (0.02) | −0.7 (0.2) |
| 5 | 1.9 | 1.4 | [−4.5,0.02] | −0.4 (0.05) | −1.4 (0.02) | −1.1 (0.2) |
| 6 | 1.8 | 1.2 | [−3.9,0.02] | −0.2 (0.05) | −1.4 (0.03) | −1.1 (0.1) |
| 7 | 1.9 | 1.5 | [−4.7,0.02] | −0.2 (0.1) | −1.4 (0.03) | −0.8 (0.2) |
| 8 | 2.0 | 1.5 | [−4.5,0.01] | −0.1 (0.1) | −1.4 (0.02) | −1.0 (0.2) |
| Median | 1.9 | 1.5 | [−4.6,0.02] | −0.2 (0.1) | −1.4 (0.02) | −1.1 (0.2) |
| Patient subgroup B | ||||||
| 9 | −1.5 (0.1) | −0.8 (0.03) | −2.0 (0.1) | |||
| 10 | −1.0 (0.1) | −0.9 (0.02) | −2.6 (0.1) | |||
| 11 | −0.4 (0.1) | −0.9 (0.03) | −2.4 (0.2) | |||
| 12 | −0.8 (0.1) | −0.9 (0.03) | −2.7 (0.2) | |||
| 13 | −1.0 (0.1) | −0.8 (0.03) | −2.6 (0.2) | |||
| 14 | −0.4 (0.1) | −1.2 (0.03) | −2.5 (0.2) | |||
| Median | −0.9 (0.1) | −0.9 (0.03) | −2.6 (0.2) | |||
Fig. 2SPR histograms for each ROI. The upper row is for patient No. 1, (Group A: Dual Source), and the lower row represents patient No. 14 (Group B: Consecutive Scanning). The mean (μ) and standard deviation (σ) for the distributions are given in the legends. These are most meaningful for the ROIs in the brain and in the eyes where the SPR distributions follow a normal distribution.